Medicalgorithmics SA stock news
Medicalgorithmics SA has executed an annex to its loan agreement with major shareholder Biofund Capital Management LLC, effectively reducing the interest rate from 18.5% to 14%. The agreement maintains the commitment to convert a 2024 loan into company equity at a price of PLN 33.00 per share, representing a premium over recent market valuations. A General Meeting of Shareholders has been convened for July 15, 2026, to formally authorize the share issuance required for this debt--to--equity conversion, a move designed to optimize the company's capital structure and reduce financial expenses.